About Moleculin Biotech
Moleculin Biotech (NASDAQ:MBRX) is a dedicated biopharmaceutical company that focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses. Their research pipeline is rich with projects that aim to bring revolutionary treatments to patients worldwide, primarily focusing on leveraging small molecule drugs to target cancer cells and viral infections effectively. One of their noteworthy objectives is to advance the science of treating cancers that have proven difficult to combat with existing medications, striving to unlock new pathways to remission and improve patient outcomes. Through rigorous research, clinical trials, and strategic partnerships, Moleculin Biotech is committed to pushing the boundaries of medicine to provide new hope for patients facing cancer and other serious diseases.
Snapshot
Operations
Products and/or services of Moleculin Biotech
- Annamycin, a next-generation anthracycline designed to avoid multidrug resistance mechanisms with a focus on treating relapsed or refractory acute myeloid leukemia.
- WP1066, an immune/transcription modulator targeting tumors with a focus on brain tumors and acute myeloid leukemia.
- WP1122, a prodrug of 2-DG (2-deoxy-D-glucose) aimed at exploiting the metabolic differences in cancer cells to treat glioblastoma and potentially other cancers.
- WP1220, a topical treatment for cutaneous T-cell lymphoma, offering a direct approach to suppress tumor growth in the skin.
- WP1234, a novel compound targeting a wide range of tumors, including pancreatic cancer, through unique mechanisms of action.
Moleculin Biotech executive team
- Mr. Walter V. KlempCo-Founder, Chairman, President & CEO
- Mr. Jonathan P. Foster CPAExecutive VP & CFO
- Dr. Donald H. Picker Ph.D.Chief Scientific Officer
- Dr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory Board
- Dr. John Paul Waymack M.D., Sc.D.Senior Chief Medical Officer